Mikheeva G N, Khaitov R M
Ter Arkh. 1998;70(4):54-60.
The study of clinicoimmunological features of current course of atopic diseases (AD) and design of effective etiopathogenic scheme of treating AD complicated by secondary immunodeficiency (SID).
After comprehensive clinical, instrumental, x-ray, functional and bacteriological investigations 186 AD patients were divided into 4 groups: 25 patients untreated by immunomodulators (controls), 35 patients treated by diuciphone (200 g i.m. each other day for 12 days), 83 patients treated by polyoxidonium (6 mg i.m. each other day for 12 days, a total course dose 30 mg, or 6 mg i.m. daily for 2 days then 6 mg each other day for 3 days then 6 mg twice a week for 14 days, a course dose 45 mg), 33 patients received likopid (1 or 10 mg daily per os for 10 days or 10 mg daily for 10 days then 2 mg twice a week for 14 days).
A scheme of combined 3-staged treatment of AD complicated by SID is suggested. Stage 1-conventional treatment inhibiting aggravation of atopic reaction, improving functional condition of the defense systems plus antiinfection therapy, immunomodulators. Stage 2-primarily specific immunotherapy. Stage 3-outpatient prophylaxis of immunodeficiency and resistant forms of atopic reactions.
Combined staged pharmacological and immunological control of allergic inflammation and immunodeficiency is the main principle of control of AD with SID.
研究特应性疾病（AD）当前病程的临床免疫学特征，并设计治疗合并继发性免疫缺陷（SID）的AD的有效病因治疗方案。
在进行全面的临床、仪器、X线、功能和细菌学检查后，186例AD患者被分为4组：25例未接受免疫调节剂治疗的患者（对照组），35例接受双醋苯二酚治疗的患者（每隔一天肌肉注射200mg，共12天），83例接受聚氧化乙烯治疗的患者（每隔一天肌肉注射6mg，共12天，总疗程剂量30mg；或每天肌肉注射6mg，共2天，然后每隔一天注射6mg，共3天，然后每周两次注射6mg，共14天，疗程剂量45mg），33例接受利可匹德治疗的患者（每天口服1或10mg，共10天；或每天口服10mg，共10天，然后每周两次口服2mg，共14天）。
提出了一种治疗合并SID的AD的三阶段联合治疗方案。第一阶段——常规治疗，抑制特应性反应加重，改善防御系统功能状态，加抗感染治疗、免疫调节剂。第二阶段——主要是特异性免疫治疗。第三阶段——门诊预防免疫缺陷和特应性反应的耐药形式。
对变应性炎症和免疫缺陷进行联合分阶段药理和免疫控制是治疗合并SID的AD的主要原则。
